Valproate-induced hyperammonemic encephalopathy versus asymptomatic hyperammonemia in adults with epilepsy: a cross-sectional study
- 1Affiliated Hospital of Jiangsu University
Abstract
Background and ObjectiveTo compare clinical features of valproate (VPA)-induced hyperammonemic encephalopathy and asymptomatic hyperammonemia to inform monitoring strategies.
MethodsThis cross-sectional study at Affiliated Hospital of Jiangsu University included 25 adults with epilepsy hospitalized between January 2024 and March 2026 with serum ammonia >33 mol/L during VPA therapy. Nine met predefined VPA-induced hyperammonemic encephalopathy (VHE) criteria; 16 had asymptomatic hyperammonemia. Clinical, laboratory, electroencephalography (EEG), and neuroimaging parameters were compared.
ResultsVHE patients had higher ammonia (median 76.0 [IQR 51.2-155.7] vs 42.5 [33.5-66.0] mol/L; P<0.001) and shorter VPA duration (median 0 [0-60] vs 30 [0-120] months; P=0.005) than asymptomatic patients. Crucially, VPA trough concentrations and liver enzymes did not differ between groups. Diffuse EEG slowing occurred exclusively in VHE patients(66.7% vs 0%; P<0.001); prior cerebral infarction was more frequent in VHE (88.9% vs 43.8%; P=0.040). All VHE patients improved clinically within 1-3 days and achieved ammonia normalization within 3-10 days after VPA withdrawal without specific ammonia-lowering therapy.
ConclusionsVHE typically emerges early in VPA therapy, is unpredictable by routine therapeutic drug monitoring or liver function tests, and resolves rapidly upon discontinuation. Clinicians should maintain a low threshold for ammonia testing in patients with new neurological symptoms during early VPA treatment, particularly those with prior cerebrovascular disease or diffuse EEG slowing. These findings support integrating ammonia screening into VPA safety protocols beyond standard therapeutic drug monitoring.
Key PointsO_LIElevated blood ammonia levels during valproate therapy do not reliably predict the presence of brain-related symptoms, as some patients remain entirely asymptomatic despite significant laboratory abnormalities. C_LIO_LIClinical decisions should be guided by observable changes in mental status and behavior rather than ammonia test results alone, to avoid both unnecessary treatment and delayed recognition of true drug-induced encephalopathy. C_LIO_LIRoutine monitoring for adults on valproate should pair laboratory testing with regular assessment of cognitive function, ensuring that symptomatic cases are promptly identified while avoiding over-intervention in stable patients. C_LI
Related
- The impact of Staphylococcus aureus and Escherichia coli loads on semen quality in asymptomatic men: A cross-sectional study
- Scapular dyskinesis with preserved structure and function in largely asymptomatic junior elite tennis players: a 2D video and multimodal cross-sectional study
- Diagnostic Yield of Opportunistic Upper Gastrointestinal Endoscopy During Elective Colonoscopy in Asymptomatic Patients: A Retrospective Cross-Sectional Study.
- Perceptions of Filipino Physicians on Screening for Musculoskeletal Disorders among Asymptomatic, Apparently Healthy Children and Adults: A Cross-sectional Study.
- Lamotrigine-associated SJS/TEN overlap during valproate co-therapy managed with rhTNFR-Fc and therapeutic plasma exchange : A case report
BibTeX
@misc{chen2026valproateinduced,
title = {{Valproate-induced hyperammonemic encephalopathy versus asymptomatic hyperammonemia in adults with epilepsy: a cross-sectional study}},
author = {H. Chen and X. Wang},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.05.26362327},
url = {https://www.medrxiv.org/content/10.64898/2026.09.05.26362327v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Valproate-induced hyperammonemic encephalopathy versus asymptomatic hyperammonemia in adults with epilepsy: a cross-sectional study
AU - H. Chen
AU - X. Wang
PY - 2026
DA - 2026/09/05
PB - medRxiv
DO - 10.64898/2026.09.05.26362327
UR - https://www.medrxiv.org/content/10.64898/2026.09.05.26362327v1
AB - Background and ObjectiveTo compare clinical features of valproate (VPA)-induced hyperammonemic encephalopathy and asymptomatic hyperammonemia to inform monitoring strategies. MethodsThis cross-sectional study at Affiliated Hospital of Jiangsu University included 25 adults with epilepsy hospitalized between January 2024 and March 2026 with serum ammonia >33 mol/L during VPA therapy. Nine met predefined VPA-induced hyperammonemic encephalopathy (VHE) criteria; 16 had asymptomatic hyperammonemia. Clinical, laboratory, electroencephalography (EEG), and neuroimaging parameters were compared. ResultsVHE patients had higher ammonia (median 76.0 [IQR 51.2-155.7] vs 42.5 [33.5-66.0] mol/L; P<0.001) and shorter VPA duration (median 0 [0-60] vs 30 [0-120] months; P=0.005) than asymptomatic patients. Crucially, VPA trough concentrations and liver enzymes did not differ between groups. Diffuse EEG slowing occurred exclusively in VHE patients(66.7% vs 0%; P<0.001); prior cerebral infarction was more frequent in VHE (88.9% vs 43.8%; P=0.040). All VHE patients improved clinically within 1-3 days and achieved ammonia normalization within 3-10 days after VPA withdrawal without specific ammonia-lowering therapy. ConclusionsVHE typically emerges early in VPA therapy, is unpredictable by routine therapeutic drug monitoring or liver function tests, and resolves rapidly upon discontinuation. Clinicians should maintain a low threshold for ammonia testing in patients with new neurological symptoms during early VPA treatment, particularly those with prior cerebrovascular disease or diffuse EEG slowing. These findings support integrating ammonia screening into VPA safety protocols beyond standard therapeutic drug monitoring. Key PointsO_LIElevated blood ammonia levels during valproate therapy do not reliably predict the presence of brain-related symptoms, as some patients remain entirely asymptomatic despite significant laboratory abnormalities. C_LIO_LIClinical decisions should be guided by observable changes in mental status and behavior rather than ammonia test results alone, to avoid both unnecessary treatment and delayed recognition of true drug-induced encephalopathy. C_LIO_LIRoutine monitoring for adults on valproate should pair laboratory testing with regular assessment of cognitive function, ensuring that symptomatic cases are promptly identified while avoiding over-intervention in stable patients. C_LI
ER -